Drug Profile
PD 158780
Alternative Names: PD158780Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator New York University; Nonindustrial source; Pfizer
- Developer New York University; Unknown
- Class Antineoplastics; Pyrimidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 4 receptor antagonists; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Angelman syndrome
- Discontinued Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Angelman-syndrome in USA (Infusion)
- 01 Aug 2012 Preclinical trials in Angelman syndrome in USA (unspecified route) before August 2012
- 01 Aug 2012 Pharmacodynamics data from a preclinical trial in in Angelman syndrome released by New York University